Results 131 to 140 of about 175,253 (265)

Toward Nano‐Nutritional Medicine: A Remotely Activated Trans‐Vaccenic Acid‐Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy

Advanced Science, EarlyView.
Eutectic mixtures from trans‐vaccenic acid (TVA) and stearic acid, which served as phase‐change material to encapsulate IR780, forming NIR‐responsive nanoparticles. IR780@TVA LNPs induce photothermal therapy and initiate adaptive anti‐tumor immunity.
Kang Liu, Yunlong Li, Hanmeng Liu, Peng Zhang, Mingjing Wang, Quanwei Sun, Wenshuo Yang, Zhengwei Song, Song Tan, Ye Yang, Peng She, Dengke Yin, Wei Shen   +12 more
wiley   +1 more source

Targeting non-canonical antigens unlocks functional T-cell responses in renal cell carcinoma. [PDF]

J Immunother Cancer
Wang J, Zhu Y, He X, Yin S, He Y, Yao P, Li J, Li X, Shi P, Qian R, Xiao Z, Ye X, Xi JJ, Ye B.   +13 more
europepmc   +1 more source

CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors

Advanced Science, EarlyView.
Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen, Xiaoyun Luo, Huixin Gao, Yujing Ke, Yu Zhan, Xiaoting Xu, Xiaoxiao Xiong, Fengjiao Wei, Si Yang, Zhonghua Liu, Bolan Yu, Zhaofeng Huang, Yingjie Bian   +12 more
wiley   +1 more source

HACC-TNF-α-VLP Nanoparticles Facilitate HSP90-Dependent Antigen Cross-Presentation to Enhance CD8⁺ T Cell and Mucosal Immunity Against Foot-and-Mouth Disease. [PDF]

Int J Nanomedicine
Lv L, Su Y, Chen S, Su W, Yin Y, Ning P, Liu S, Yuan W, Li L.   +8 more
europepmc   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

Micropeptide colorectal neoplasia differentially expressed (CRNDE) 84aa encoded by CRNDE elicits a T-cell immune response to breast cancer. [PDF]

Transl Cancer Res
Zeng L, Hu P, Bai C, Luo Y, Fang X, Liu X, Yuan Q, Zhu X.   +7 more
europepmc   +1 more source

Targeting Lactate‐Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
Tumor‐derived lactate activates PSCs through MCT1‐mediated Vps34 lactylation and autophagy. These activated PSCs secrete CXCL9/10, upregulating PD‐1 on CD8+ T cells via the CXCR3/STAT3 axis to foster immunosuppression. Disrupting this metabolic crosstalk by targeting MCT1 effectively sensitizes pancreatic cancer to PD‐1 blockade, presenting a promising
Wenfeng Zhuo, Rong Hu, Yuhang Hu, Ping Hu, Shengbo Han, Guozheng Lv, Zhu Zeng, Yong Zhao, Yang Li, Yan Huang, Yingsong Zhao, Hongda Wang, Guangyu Zhao, Eryang Zhao, Gang Zhao   +14 more
wiley   +1 more source

An observational study to test the potency of GLP-grade phenol-free lyophilised leishmanin antigen formulation. [PDF]

EBioMedicine
Pacheco-Fernandez T, Klenow L, Inoue SI, Singh KP, Valanezhad F, Markle H, Azodi N, Brino M, Bakytbek S, Hobson C, Jain I, Talgaonkar P, Shukla S, Kardile P, Kaviraj S, Silva LO, Borba PB, Santana M, Costa T, Matlashewski G, Carvalho LP, Carvalho EM, de Oliveira CI, Satoskar AR, Singh S, Hamano S, Gannavaram S, Nakhasi HL.   +27 more
europepmc   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source

Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity. [PDF]

Cells
Richert I, Chalus L, Pinteur B, Bravetti P, Tortorelli C, Alzeeb G, Ghiringhelli F.   +6 more
europepmc   +1 more source